Measurements of hyperpolarized 13 C label exchange between injected [1- 
C magnetic resonance spectroscopic imaging (MRSI) enable the real-time imaging of tissue metabolism in the clinic, in tumors 5 and in the heart. 6 Hyperpolarized [1- 13 C]pyruvate is the best-established substrate, mainly as a result of its relatively long polarization half-life (~30 s in vivo), rapid plasma membrane transport and subsequent metabolism. 7, 8 Pyruvate is well tolerated at relatively high concentrations and has a history of safe use in humans as well as in animals. 5 Under pathological conditions that lead to upregulated glycolysis, such as in the majority of tumors, pyruvate, which is the end product of glycolysis, is not oxidized, but is rapidly and reversibly reduced by nicotinamide adenine dinucleotide (NADH) to generate lactate, in a reaction catalyzed by lactate dehydrogenase (LDH). Similarly to FDG-PET, MRS(I) measurements of hyperpolarized 13 C label exchange between injected [1-
13
C]pyruvate and endogenous lactate have been used in cancer to detect disease and monitor disease progression, 9, 10 and to assess early tumor responses to treatment. 11, 12 The experiment has an advantage over FDG-PET in that it does not involve the use of ionizing radiation, which could allow multiple repeat measurements in an individual patient, for example to guide treatment, and it assesses a unique metabolic feature of tumors, i.e. their preference to reduce pyruvate to lactate rather than oxidize it in the mitochondrial tricarboxylic acid (TCA) cycle. FDG-PET measures glucose uptake and subsequent phosphorylation, which can be upregulated in normal tissues, such as the brain, as well as in tumors. 13 C labeling of the endogenous lactate pool following the injection of hyperpolarized [1- C]pyruvate signal ratio or by an apparent first-order exchange rate constant if the metabolite signals are analyzed as a function of time. 7, 8, 11 However, as the concentrations of labeled pyruvate and lactate cannot be determined from their signal intensities, it is not possible to determine a metabolically relevant flux, for example, in mM/s. 13 This is a problem as changes in this apparent first-order rate constant could be the result of a metabolically relevant change in isotope flux, resulting, for example, from a change in LDH concentration or a change in the concentration of pyruvate that actually reaches the exchange site. This is not a significant problem for preclinical studies as, typically, inbred strains of mice are used and, in the case of tumors, nearly identical tumors are implanted, or autochthonous tumors arise at the same site, and therefore variations in pyruvate delivery are less likely. However, this is likely to be much more of a problem in the clinic. Here, we examined this assumption in more detail and showed that there are significant levels of labeled lactate in the blood at 30 s after injection of labeled pyruvate, determined by measurement of the thermally polarized 13 C in tissue extracts.
However, 13 C imaging measurements performed with hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate in this study and previously 14 show no evidence for the appearance of labeled lactate, suggesting that it has only relatively low levels of polarization.
| METHODS

| Tumor implantation
All animal experiments were conducted in accordance with project and personal licenses issued under the UK Animals (Scientific Procedures) Act, 1986. Protocols were approved by the Cancer Research UK, Cambridge Institute Animal Welfare and Ethical Review Body.
Tumors were established by subcutaneous inoculation of a suspension of 5 × 10 6 viable EL4 murine lymphoma cells (in a volume of 100 μL) in the left flank of C57BL/6 mice (Charles River Ltd., Harlow, Essex, UK) (n = 69) at 6-8 weeks of age, when the animals were~20 g. Studies were performed when the tumors had grown to a size of~2 cm 3 , which was typically 10 days following implantation. Animals, which were not submitted to any dietary restriction, 16 were anesthetized by either inhalation of 1-2% isoflurane (Isoflo, Abbotts Laboratories Ltd., Maidenhead, Berkshire, UK) in air/O 2 (75%/ 25%, 2 L/min) or by intraperitoneal administration of 10 mL/kg body weight of a 5: 4: 31 mixture of Hypnorm (VetaPharma, Sherburn-in-Elmet, Leeds, North Yorkshire, UK), Hypnovel (Roche, Welwyn Garden City, Hertfordshire, UK) and saline (n = 5). Body temperature was maintained by blowing warm air through the magnet bore. The breathing rate (~80 beats/min) and body temperature (37°C) were monitored during the experiments (Biotrig, Small Animal Instruments, Stony Brook, New York, USA). Agents were injected intravenously via a tail vein catheter.
For some experiments (n = 6), the transport of hyperpolarized [1- 
| MRS and MRSI
Experiments were performed in a 7.0-T horizontal bore magnet (Agilent, Palo Alto, CA, USA) using an actively decoupled dual-tuned 20 where k P is a first-order rate constant describing the labeling of lactate (L) from pyruvate (P) and R 1,L describes the loss of polarization in lactate as a result of spin-lattice relaxation (R 1,L ):
To account for the effect of Prohance, a second relaxation term (R 1,Gd ) was included in the model at time points after Prohance injection (30-40 s) . To avoid any bias arising from this approach, in animals not receiving Prohance (n = 5), R 1,Gd was incorporated into the model at 35 s after pyruvate injection, which yielded a value for R 1,Gd of 0.001 ± 0.001 s -1 .
In another set of animals (n = 2), axial The data were multiplied by a cosine function and zero-filled to 128 points in both spatial directions, line-broadened to 20 Hz and zero-filled to 1024 points in the spectral dimension before Fourier transformation, phase and baseline correction and peak integration.
| Tissue and blood collection and analysis
| 13 C experiments
Perchloric acid extracts of blood and tumor tissue from EL4 tumor-bearing (n = 7) and non-tumor-bearing (n = 6) mice were prepared from animals that had been anesthetized for 30 min and then injected with [3- to another Eppendorf tube with 600 μL of 7% perchloric acid (1: 8, w/v). In another cohort of mice (n = 3, tumor-bearing; n = 4, non-tumor bearing), blood was withdrawn by cardiac puncture and 0.4 mL was added to a tube preheated to 37°C to which [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate (40 μL, 82mM) was then added rapidly and the tube was gently mixed. After 30 s, the blood samples were processed as above. In another set of animals (n = 5), anesthetized by intraperitoneal injection of Hypnorm/Hypnovel, [1-
13
C]lactate (45mM) 21 was injected intravenously into tumor-bearing animals that had received either saline (n = 3) or 4-CIN (n = 2) injections 5 min prior to lactate injection. Animals were killed 30 s later and the tumors were processed as above.
Perchloric acid extracts were prepared using ice-cold 7% perchloric acid (1: 8, w/v), which were then neutralized with KOH, lyophilized and dissolved in 99.9% deuterium oxide. The experiments in which [3- ACDSpecManager (ACD/Labs, Bracknell, Berkshire, UK). Data were zero-filled twice and multiplied by an exponential function prior to Fourier transformation. All NMR resonance areas were normalized to the integral of the 5mM TSP resonance. homogenizer (Stretton Scientific Ltd., Stretton, Derbyshire, UK) and the blood was centrifuged as described above. The counts from the tissues and serum were determined using a liquid scintillation counter (Perkin Elmer, Beaconsfield, Buckinghamshire, UK). The measured radioactivity was normalized to tissue weight or serum volume, accordingly.
| 14 C experiments
| Statistical analysis
Data are reported as the mean ± standard error of the mean (SEM). Statistical significance was tested using Prism 6 with a two-tailed Mann-Whitney test, unpaired two-tailed Student's t-test or Kruskal-Wallis test when appropriate. p < 0.05 was considered to be significant.
| RESULTS
| Biodistribution of pyruvate
The biodistribution of [1- C label in the tumor will be in the blood pool. We C] pyruvate injected intravenously (10 mL/kg; 82mM; specific activity, 50-60 mCi/mmol). EL4 tumor-bearing mice were injected at the indicated times and the tissues were harvested and weighed, and the radioactivity was counted in a scintillation counter. The total amounts of radioactivity recovered from the indicated tissues were 55.9, 57.9 and 56.1 ID%/g at 15, 30 and 60 s, respectively estimated the functional vessel volume in this tumor previously using dynamic contrast agent-enhanced MRI and by dye injection. 22 A similar pattern of labeling was observed in the heart, which may be dominated by blood present in the ventricles. The decrease in blood activity was accompanied by small increases in all the other organs analyzed, including the brain. The total amount of radioactivity recovered from all the tissues analyzed was unchanged over 60 s (Figure 1 (Figure 2) . The pyruvate peak integral in the spectrum from the aorta was 14 times greater than the pyruvate peak integral in the spectrum from the tumor. Given a tumor blood volume of~2%, the blood pyruvate signal will contribute~30% of the total tumor pyruvate signal (see broken line
in Figure 2B ).
| Concentrations of 13
C-labeled pyruvate and lactate in tumor and blood H image of tissue water. The blood vessel (yellow), tumor (red) and bowel (blue) regions are outlined. The false-color images show the intensities of the pyruvate (172.9 ppm) and lactate (185.1 ppm) signals normalized to the maximum pyruvate signal in the slice. A lactate image from the same slice, multiplied by a factor of five, is also shown. Summed spectra from the blood vessel, bowel and tumor regions are shown below the corresponding images (B). The y-scale for the bowel and tumor spectra has been multiplied by a factor of five to aid visualization. The broken line in the tumor spectrum shows the blood vessel spectrum, which has been scaled to take account of the fact that the blood volume is~2% of the tumor volume With a blood volume that is only 2% of the tumor volume, the labeled lactate and pyruvate concentrations in the blood pool (3.6 μmol/g) at 30 s will make only an~10% contribution to the concentrations measured in the tumor (0.78 μmol/g). This is consistent with our failure to detect any 13 Clabeled pyruvate in the tumor (Table 1) . To determine the relative contributions of blood cells and other tissues to the lactate labeling observed in the blood pool, we added 3.28 μmol of [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate to 0.44 mL of freshly drawn blood obtained by cardiac puncture and measured labeling in pyruvate and lactate after incubation at 37°C for 30 s (Table 2 ). In blood from tumor-bearing and non-tumor-bearing animals, 10% (1.2 μmol/g) and 9% (0.6 μmol/g), respectively, of the lactate became labeled (Table 2) . Therefore, isotope exchange catalyzed by blood can account for approximately one-half of the 13 C-labeled lactate observed in the blood pool at 30 s after injection of labeled pyruvate, the remainder presumably coming from 13 C label exchange in other tissues.
| Compartmentalization of hyperpolarized [1-13 C]lactate
Sequential injections of hyperpolarized [1-
13
C]pyruvate (10 mL/kg, 82mM) (n = 4), followed~35 s later by a gadolinium chelate (~0.75 mmol/kg Prohance), were used to investigate the distribution of labeled lactate between intra-and extracellular pools in the tumors. 18, 19, 28 Previous reports have indicated that the rate of lactate transport to the extracellular compartment is only slightly slower than the rate of labeled lactate formation, 19 and we have shown previously in EL4 tumor cells that transport and LDH activity have similar flux control coefficients for the exchange of hyperpolarized 13 C label. 24 Injection of the gadolinium chelate resulted in an increased rate of decay of the lactate signal, which could not be explained simply by the accelerated loss of pyruvate polarization (Figure 3 ). The broken lines in Figure 3 show the lactate signal that would have been observed based on the observed pyruvate signal and assuming that k P does not change following the injection of the gadolinium chelate. This is consistent with some fraction of the lactate signal coming from the extracellular compartment, which will be predominantly the interstitial space, given the low blood volume. The administration of an MCT inhibitor (4-CIN; 150 mg/kg, 0.2 mL intravenously), 3 min (n = 2) or 30 min (n = 4) prior to the injection of hyperpolarized [1-13 C]pyruvate (10 mL/kg, 82mM) (n = 6), led to a 30% decrease (p < 0.05) in the apparent first-order rate constant (k P ) describing the flux of hyperpolarized 13 C label between the injected pyruvate and endogenous lactate pool (Table 3) , consistent with 4-CIN inhibition of pyruvate uptake. 17, 29 This inhibitor, which inhibits predominantly MCT1, also inhibits lactate transport, which was confirmed by the injection of 4-CIN 5 min prior to the injection of thermally polarized [1- 0.1mM, p < 0.05, n = 2) when compared with controls treated with saline (2 ± 0.5mM, n = 3). There were no changes in the total tumor lactate concentration (12 ± 1mM). We have shown previously that EL4 tumors express both MCT1 and MCT4. 24 The inhibition of lactate transport with 4-CIN decreased the apparent rate of decay of polarization in [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]lactate from 0.056 ± 0.004 to 0.041 ± 0.003 s -1 (p < 0.05) ( Table 3 ).
| DISCUSSION
The exchange of hyperpolarized 13 C label between injected [1-
13
C]pyruvate and the endogenous lactate pool is usually characterized by an apparent first-order rate constant, 11, 17, 30 or by the ratio of the area under the lactate and pyruvate labeling curves, which is directly related to this rate C]pyruvate were taken and the blood was used to measure exchange in the blood pool (Table 2) . n.q., not quantifiable; n, number of animals.
a Significantly different compared with levels in the blood of non-tumor-bearing mice; mean ± standard deviation (SD); p < 0.01. 13 
C-labeled lactate (% of total)
Tumor-bearing mice (n = 3) 7 ± 3 12 ± 3 88 ± 2 10 ± 2
Non-tumor-bearing mice (n = 4) 7.8 ± 2.2 7 ± 3 92 ± 7 9 ± 2 [3-13 C]Pyruvate (3.28 μmol) was added to 0.44 mL of freshly withdrawn blood and incubated at 37°C for 30 s. The tissue was then extracted in perchloric acid and 13 C labeling was analyzed by 13 C nuclear magnetic resonance (NMR) measurements on neutralized extracts.
constant. 15 The rate constant is an apparent rate constant as it is an empirical measure of a process that includes pyruvate delivery to the tissue, uptake into the cell and subsequent LDH-catalyzed exchange of the hyperpolarized 13 C label with lactate. As the rate of exchange is spatially heterogeneous, 11 and in the absence of any imaging measurements, this apparent measured rate constant is also a reflection of the average rate for the whole tumor. However, it is not a measure of the metabolically relevant flux, measured for example in mM s -1 , as a change in this apparent rate constant may indicate a change in flux or a change in the concentration of pyruvate at the exchange site. In order to obtain a true isotope flux measurement, we need to know the concentration of pyruvate at the exchange site, which measurements with hyperpolarized [1- C-labeled pyruvate as it was below the level of detection (Table 1) . However, as measurements of 13 C label in blood pyruvate and lactate (22% ID/g) were comparable with measurements of 14 C label in the blood pool (15% ID/g), this suggests that the measurements of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]
pyruvate at the tumor site can provide a surrogate measure that can be used to approximate the concentration of pyruvate. 32 However, the challenge would be to acquire the PET data sufficiently rapidly to obtain an estimate of the tumor pyruvate concentration The reported value is calculated only for animals receiving Prohance (n = 4). For control animals not receiving Prohance (n = 5), R 1,Gd was 0.001 ± 0.001 s -1 .
during the time in which the MR measurements of hyperpolarized 13 C label exchange were being made and before there was significant loss of Previous diffusion measurements on EL4 tumors have shown that the labeled lactate observed following the injection of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate has a lower diffusion coefficient than pyruvate, suggesting that the labeled lactate is predominantly intracellular. 17 However, the reported diffusion coefficients in this previous study for pyruvate were slightly lower and for lactate slightly higher than those measured previously using 1 H diffusion spectroscopy for purely vascular or intracellular metabolites, respectively, [34] [35] [36] suggesting that the observed lactate was present in both the interstitial and intracellular spaces. That the tumor can release significant amounts of labeled lactate was confirmed here by the injection of a gadolinium chelate, Prohance, 35 s following the injection of hyperpolarized [1- in Day et al.
11
). The relatively rapid release of lactate from the tumor cells is interesting in view of the growing evidence for a symbiotic relationship between aerobic and hypoxic cancer cells within the same tumor, with lactate shuttling between these two cell populations. 39 There has also been a recent suggestion that cancer cells with high glycolytic activity have a capacity to evade immunosurveillance by diminishing T-cell anti-tumor responses.
40,41
The inhibition of MCT activity by 4-CIN was demonstrated by showing inhibition of lactate labeling following injection of hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate (Table 3 ) and also by showing the inhibition of tumor uptake of thermally polarized [1- Table 2 ). The remainder of the labeled blood lactate presumably arose from lactate that underwent exchange in other tissues and was then released into the blood pool. The labeled lactate concentration at 30 s was approximately twice the concentration of 13 C-labeled pyruvate at this time point (1.2 μmol/g) ( Table 1) . CSIs acquired here, 15 s earlier (Figure 2) , and a time course of single-shot three-dimensional images acquired previously at 2-s intervals up to 60 s after hyperpolarized [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]pyruvate injection, 14 showed that the majority of observable pyruvate was in blood; the intense signal in the aorta in Figure 2 should be noted, whereas labeled lactate was largely absent from the aorta and was more homogeneously distributed throughout the body, with a large fraction in the tumor. The implications of these observations are that labeled lactate released into the circulation at early time points is too low in concentration to be detected and at later time points has lost a substantial amount of polarization.
| CONCLUSIONS
We have shown that only a small fraction of injected 13 C-labeled pyruvate reaches the tumor and the pyruvate that enters the cell rapidly exchanges its 13 C label with lactate in the reaction catalyzed by LDH, the label becoming substantially diluted in the large endogenous lactate pool.
Estimation of the pyruvate concentration in the tumor and multiplication of this concentration by the apparent first-order rate constant (k P )
describing the exchange of hyperpolarized 13 C label between injected [1-13 C]pyruvate and the endogenous lactate pool gave a label flux that was in good agreement with that determined directly by measurement of the concentration of 13 C label incorporated into lactate in tumor extracts.
This suggests that simultaneous PET/MR studies in the clinic with hyperpolarized [1- 
